IRADIMED CORPORATION (NASDAQ:IRMD), the leading provider of non-magnetic
intravenous (IV) infusion pump systems that are safe for use during
magnetic resonance imaging (MRI) procedures, announced that it has
closed its initial public offering of 2,318,400 shares of common stock
at a price of $6.25 per share, including 302,400 shares sold pursuant to
the over-allotment option exercised in full by the underwriters of the
initial public offering. Shares began trading on the NASDAQ Capital
Market under the symbol IRMD on July 16, 2014.
Roth Capital Partners acted as sole book-running manager for the
offering and Monarch Capital Group acted as co-manager.
The common stock was issued pursuant to a registration statement on Form
S-1, which was declared effective by the Securities and Exchange
Commission on July 15, 2014. Copies of the written prospectus for the
offering may be accessed through the Securities and Exchange
Commission's website at www.sec.gov,
or may be obtained from Roth Capital Partners, 888 San Clemente Drive,
Suite 400, Newport Beach, CA 92660, firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or jurisdiction.
About IRADIMED CORPORATION
IRADIMED CORPORATION is the leading provider of non-magnetic IV infusion
pump systems that are safe for use during MRI procedures.
Electromechanical medical devices and pumps contain magnetic and
electronic parts which generate radio frequency noise, create
interference and are dangerous to operate in the presence of the
powerful magnet which drives an MRI. The company's mRidium (3850/3860+)
IV pump systems have been designed with non-ferrous parts, ceramic
ultrasonic motors, non-magnetic mobile stand and other special features
in order to safely and predictably deliver anesthesia and other IV
fluids during various MRI procedures. The company's pump solution
provides a seamless approach to providing IV fluids before, during and
after an MRI scan, which is important to critically-ill patients who
cannot be removed from their vital medications, and children and infants
must generally be sedated in order to remain immobile during an MRI
scan. For more information please visit www.iradimed.com.
mRidium is a trademark of IRADIMED CORPORATION.
[ Back To NFVZone's Homepage ]